Reviva Enrollment Update for Pivotal Phase 3 Schizophrenia Study

  Enrollment ongoing at multiple sites in the US and Europe; site initiation in Asia expected in November 2022 -

- Enrollment on pace, with over 30% enrolled in the United States -

- Topline data for RECOVER evaluating brilaroxazine for schizophrenia expected in mid-2023 -

https://finance.yahoo.com/news/reviva-pharmaceuticals-announces-global-enrollment-120000187.html